Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 186 HER2-positive Breast Cancer 18 Neoplasm Metastasis 6 Inflammatory Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Neoplasms 4 Prostatic Neoplasms 3 Pathologic Complete Response 3 Pancreatic Neoplasms 3 HER2-positive Early Breast Cancer 3 Endometrial Neoplasms 3 Breast Neoplasms, Male 3 Anatomic Stage I Breast Cancer AJCC v8 3 Stomach Neoplasms 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Locally Advanced Breast Cancer 2 Hematologic Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Gastrointestinal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Ductal, Breast 2 Breast Diseases 2 Brain Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thrombocytosis 1

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × pertuzumab × Breast × Clear all

NCT04208178 2026-04-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡